Earnings ·
Vera Therapeutics reported a net loss of $109.5 million for the second quarter ended June 30, 2026, compared to a…
VERAVera Therapeutics, Inc.
Vera Therapeutics reported a net loss of $109.5 million for the second quarter ended June 30, 2026, compared to a $76.5 million loss in the prior year period. The company announced the commercial launch of TRUTAKNA, its first FDA-approved therapy for IgA nephropathy (IgAN), and aligned with regulators on an earlier final efficacy analysis from the ORIGIN 3 trial expected in Q3 2026 to support full approval. Vera also appointed Nancy Boman as Chief Regulatory Officer, succeeding William Turner who is transitioning to Strategic Advisor. The company held $499.2 million in cash and marketable securities at quarter-end. Vera Therapeutics operates in the biotechnology industry, focusing on developing therapies for autoimmune diseases.